Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$3.03 USD
+0.01 (0.33%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $3.03 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Cellectar Biosciences, Inc. [CLRB]
Reports for Purchase
Showing records 21 - 40 ( 120 total )
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Corp Update Guides Pivotal Data in 2H23, Oulines Recent Pipeline Progress
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
1Q23: Awaiting Phase 3 Iopofosine Results in WM, Funded Into 4Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
4Q22: Awaiting Phase 3 Iopofosine Results in WM, Funded Into 4Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Complete Response Seen In Rel/Ref Primary CNS Lymphoma Patient
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Presents CLR 12120 Targeted Alpha- Emitting Agents at World ADC Conference
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Focus on Topline Readout From WM Study; Adjust PT Up to $4.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
3Q22: Expecting Positive Pivotal Data In A Few Months, Funded Into 4Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
NCI Awards $2M More to Fund Phase 1 Pediatric Glioma Trial Continuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Phase 2 Data Publication Underscores Iopofosine Potential in MM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
2Q22: Funded Into 3Q23, Undervalued Given Pivotal Trial''s Success Chances
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Updating Model Due To 1 for 10 Reverse Stock Split, Price Target Now $40
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J